Business Wire

CA-ANOMALI

1.8.2022 11:02:08 CEST | Business Wire | Press release

Share
Anomali Appoints Cyber Security Expert Steve Benton as Vice President and General Manager to Expand Growth of Anomali Intelligence-Driven Solutions

Anomali , a leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions, today announced that Steve Benton has been appointed to the position of Vice President of Anomali Threat Research (ATR) and General Manager of the Anomali Belfast, Ireland Office. Benton, an experienced cyber security expert has a history of strategic advisory, intelligence sharing and coordinated response across MD, CxO, and board audiences. Benton joins Anomali during a time of rapid global expansion, to deliver guidance to global organizations on investment, strategy and making security a business enabler to rapidly address the evolving global threats of today and in the future.

“Steve brings a wealth of experience to Anomali – both in cybersecurity and in building and contributing to the wider security community. His experience and expertise spanning cyber security advisory, thought leadership, strategic development and execution will be a tremendous asset to our customers, partners, and investors,” said Mark Alba, CPO. “Steve’s extensive experience and expertise has been instrumental in helping guide global organizations on what is required to operate successfully in an ever-increasing and complex threat environment. We are very excited about Steve playing a pivotal role in how Anomali solutions can further help customers to thrive, grow and face security challenges with confidence.”

Benton has more than three decades of experience working with customers to solve their most difficult security challenges. Most recently, Benton was Deputy CISO and latterly CSO for BT where he was accountable for physical and cyber security across investment, posture, and response globally. While at BT, he built and led the Protect BT Services and Operations organization spanning intelligence, offensive security, cyber security operations, physical security operations, strategy, investigations, and incidents. In addition, he innovated proactive threat hunting and wide-ranging intelligence operations to anticipate threats, track threat actors, and their methods. An industry security expert, Benton is a contributing member of the Cyber Defenders Council, Fellow of the Chartered Institute of Information Security and a regular speaker and influencer to the i4 C level community.

“I am excited to join Anomali, the leader of threat-intelligence driven solutions, and contribute to the mission of helping organizations efficiently and effectively stop breaches and advanced adversaries,” said Benton. “As a previous customer, I leveraged the Anomali portfolio at the heart of my drive to improve security posture and disrupt threat actor activities at pace, whilst driving the democratisation of threat intelligence across the business. To know yourself and your adversaries through high fidelity, actionable intelligence, that constantly informs your decisions and guides a dynamic security posture, is the new battleground. And I look forward to bringing my frontline operational and strategic experience to Anomali customers and partners. With cyberattacks on the rise, ever more complex and multidimensional, organizations require an integrated XDR solution to tell them who they are up against, why, when they are being attacked, and how to accelerate their multifaceted response. The Anomali Platform greatly enhances an organization’s ability to address newly detected attacks, cresting threats and subsequent future attacks. Put simply, confidence in the face of uncertainty.”

For more information, visit:
www.anomali.com

Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog

About Anomali

Anomali is the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions. Anchored by big data management (the “X”) and refined by artificial intelligence, The Anomali Platform, an XDR solution, delivers unique proprietary capabilities that correlate the largest repository of global intelligence with telemetry from customer-deployed security solutions. This combination empowers security operations teams to detect threats with precision, optimize response, achieve resiliency, and ultimately stop attackers and breaches. Our SaaS-based solutions easily integrate into existing security tech stacks through native-cloud, multi-cloud, on-premises, and hybrid deployments. Founded in 2013, Anomali serves global B2B enterprise businesses and large public sector organizations, ISACs, ISAOs, service providers, and Global 1000 customers to help safeguard the world’s critical infrastructure, businesses, and people. Leading venture firms, including Google Ventures, General Catalyst, and IVP, back Anomali.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye